ALLO Allogene Therapeutics, Inc. Stock Quote

ALLO [NASD]

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	0.50%	Shs Outstand	127.14M	Perf Week	1.82%
Market Cap	4.71B	Forward P/E	-	EPS next Y	-2.45	Insider Trans	-33.17%	Shs Float	70.29M	Perf Month	19.71%
Income	-242.70M	PEG	-	EPS next Q	-0.56	Inst Own	61.50%	Short Float	18.55%	Perf Quarter	-6.68%
Sales	-	P/S	-	EPS this Y	-4.90%	Inst Trans	0.11%	Short Ratio	14.29	Perf Half Y	-14.49%
Book/sh	8.80	P/B	3.75	EPS next Y	-16.10%	ROA	-25.00%	Target Price	48.92	Perf Year	40.88%
Cash/sh	5.88	P/C	5.61	EPS next 5Y	1.00%	ROE	-27.60%	52W Range	17.43 - 55.00	Perf YTD	30.67%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-37.87%	Beta	-
Dividend %	-	Quick Ratio	17.00	Sales past 5Y	-	Gross Margin	-	52W Low	96.04%	ATR	1.63
Employees	264	Current Ratio	17.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	69.06	Volatility	5.52% 5.57%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-4.90%	Profit Margin	-	Rel Volume	2.17	Prev Close	32.98
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 BMO	Payout	-	Avg Volume	912.06K	Price	34.17
Recom	1.90	SMA20	19.41%	SMA50	15.79%	SMA200	-3.72%	Volume	480,010	Change	3.61%

Jan-26-21

Upgrade

Stifel

Hold → Buy

$33 → $43

Dec-10-20

Resumed

H.C. Wainwright

Buy

$40

Nov-24-20

Initiated

BofA Securities

Buy

$41

Oct-23-20

Initiated

RBC Capital Mkts

Outperform

$55

Jun-01-20

Downgrade

Raymond James

Outperform → Mkt Perform

May-29-20

Reiterated

H.C. Wainwright

Buy

$42 → $55

May-19-20

Upgrade

ROTH Capital

Neutral → Buy

$26 → $60

May-15-20

Upgrade

Guggenheim

Neutral → Buy

May-14-20

Reiterated

H.C. Wainwright

Buy

$35 → $42

May-14-20

Downgrade

SunTrust

Buy → Hold

$29 → $32

Apr-13-20

Initiated

SunTrust

Buy

$29

Mar-13-20

Initiated

H.C. Wainwright

Buy

$35

Mar-05-20

Initiated

Stifel

Hold

$27

Feb-24-20

Initiated

Berenberg

Hold

$27

Dec-18-19

Initiated

JMP Securities

Mkt Outperform

$37

Nov-04-19

Initiated

Canaccord Genuity

Buy

$36

Aug-09-19

Initiated

BTIG Research

Buy

$37

Jun-05-19

Initiated

ROTH Capital

Neutral

$26

May-31-19

Initiated

Guggenheim

Neutral

May-23-19

Initiated

Stifel

Hold

Jan-26-21 08:30AM	Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine GlobeNewswire
Jan-10-21 11:35PM	Who Has Been Buying Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares? Simply Wall St.
Jan-05-21 08:30AM	Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-20 10:47AM	Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod Zacks
Dec-23-20 11:30AM	Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma GlobeNewswire
Dec-18-20 09:30PM	Is ALLO A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-15-20 06:00AM	Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T Cell Therapies GlobeNewswire
Dec-07-20 12:40PM	Race for Multiple Myeloma Drugs Not Moving Stocks Yet Barrons.com -13.64%
10:00AM	Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR T Cell Therapy, at the 62nd Meeting of the American Society of Hematology GlobeNewswire
Dec-06-20 10:00AM	Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology GlobeNewswire
Dec-05-20 12:30PM	Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting GlobeNewswire
Dec-04-20 11:31AM	Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue? Zacks
Dec-02-20 08:30AM	Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 GlobeNewswire
Nov-12-20 08:30AM	Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation GlobeNewswire
Nov-08-20 11:04AM	Goldman Sachs: These 2 Stocks Have the Potential to Rally Over 40% TipRanks
Nov-04-20 12:44PM	Allogene Drops After Analyst Review of Drug-Trial Results TheStreet.com -8.08%
09:52AM	Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses Zacks
09:03AM	Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology GlobeNewswire
07:30AM	Allogene Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire
06:45AM	Allogene Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-27-20 08:30AM	Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020 GlobeNewswire
Oct-24-20 08:55AM	Is CRISPR Therapeutics a Good Biotech Stock to Buy Now? Motley Fool
Oct-21-20 10:02AM	Crispr Therapeutics Gene-Edited Treatment Stopped Cancer in Some Patients Barrons.com
Oct-15-20 08:00AM	Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T) GlobeNewswire -8.34%
Sep-29-20 06:48PM	Hedge Funds Are Piling Into Allogene Therapeutics, Inc. (ALLO) Insider Monkey
Sep-04-20 11:31AM	Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound? Zacks
Sep-02-20 08:30AM	Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation GlobeNewswire
Aug-06-20 11:19AM	Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses Zacks
Aug-05-20 07:30AM	Allogene Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-29-20 09:27AM	4 Companies That Could Upend the Pharma Industry Motley Fool
Jul-28-20 08:30AM	Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020 GlobeNewswire
Jul-20-20 08:30AM	Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics PR Newswire
Jul-15-20 07:55AM	Did Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insiders Buy Up More Shares? Simply Wall St.
Jul-07-20 08:30AM	Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board GlobeNewswire
Jul-05-20 03:31PM	Allogene Therapeutics, Inc. (ALLO): Hedge Funds Sticking Around Insider Monkey
Jul-01-20 10:54AM	Insider Sells Allogene Therapeutics Shares Benzinga
08:30AM	Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Councils Stevin Prize GlobeNewswire
Jun-26-20 03:30PM	Insiders Roundup: Salesforce, Mastercard GuruFocus.com
11:30AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-22-20 04:30PM	Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR at the American Association for Cancer Research (AACR) Virtual 2020 Meeting GlobeNewswire +7.02%
08:30AM	Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia GlobeNewswire
Jun-14-20 11:38AM	Top Insider Buys Highlight for the Week of June 12 GuruFocus.com
07:00AM	4 Biotech Stocks That Are Seeing Big Buys in June Barrons.com
Jun-10-20 11:30AM	Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year? Zacks
Jun-05-20 11:32AM	Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report? Zacks
Jun-03-20 08:30AM	Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation GlobeNewswire
Jun-02-20 07:14AM	Allogene Seeks To Raise $550 Million From Share Sale Priced At $47 SmarterAnalyst
Jun-01-20 09:05PM	Allogene Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
11:52AM	Why Allogene Therapeutics Is Trading Lower Today Benzinga
06:30AM	Allogene Therapeutics Announces Commencement of Public Offering of Common Stock GlobeNewswire
06:02AM	Cancer Summit Presses Toward Treatments in Covids Shadow Bloomberg
May-29-20 10:32AM	Traders Sift Through Virtual Cancer Meetings Winners and Losers Bloomberg
08:00AM	Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-28-20 11:21AM	Venture Funding of Drug Startups Down, But Not Out GuruFocus.com -5.00%
May-27-20 10:02AM	Moving Average Crossover Alert: Allogene Therapeutics Zacks
May-26-20 04:30PM	Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020 GlobeNewswire -8.68%
May-22-20 11:30AM	Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year? Zacks +7.65%
May-19-20 08:55AM	Implied Volatility Surging for Allogene (ALLO) Stock Options Zacks
May-18-20 09:22AM	Allogene Therapeutics (ALLO) in Focus: Stock Moves 6.6% Higher Zacks +7.64%
May-15-20 07:49AM	The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO Benzinga +6.62%
May-14-20 01:06PM	Here's Why Allogene Therapeutics Is Roaring Higher Today Motley Fool +35.96%
04:20AM	Allogene Explodes 28% After-Hours On Initial ALLO-501 Data SmarterAnalyst
May-13-20 05:00PM	American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma GlobeNewswire
10:54AM	Will Allogene Therapeutics Continue to Surge Higher? Zacks
May-11-20 08:30AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry Zacks +6.34%
May-07-20 10:51AM	Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses Zacks
08:01AM	Allogene Therapeutics Inc (ALLO) Q1 2020 Earnings Call Transcript Motley Fool
May-06-20 07:30AM	Allogene Therapeutics Reports First Quarter 2020 Financial Results GlobeNewswire
May-05-20 11:45AM	Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More Zacks
11:40AM	5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates Zacks
08:43AM	Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO) Zacks
Apr-29-20 11:54AM	Is a Beat in Store for Amarin (AMRN) This Earnings Season? Zacks +5.94%
11:43AM	Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology GlobeNewswire
Apr-28-20 04:39PM	Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting GlobeNewswire -7.51%
Apr-27-20 08:30AM	Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020 GlobeNewswire
Apr-22-20 07:15AM	Allogene's Shares March Higher, Can It Continue? Zacks +5.68%
Apr-17-20 11:30AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Zacks +5.99%
Apr-16-20 12:00PM	Here's Why Momentum Investors Will Love Allogene Therapeutics (ALLO) Zacks
Apr-01-20 08:30AM	Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences GlobeNewswire -5.40%
Mar-28-20 09:10PM	Hedge Funds Have Never Been This Bullish On Allogene Therapeutics, Inc. (ALLO) Insider Monkey
Mar-24-20 07:00AM	MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T) Therapies PR Newswire
Mar-23-20 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-20-20 08:54AM	Why You Shouldn't Bet Against Allogene Therapeutics (ALLO) Stock Zacks -5.13%
Mar-17-20 06:30AM	We're Not Very Worried About Allogene Therapeutics's (NASDAQ:ALLO) Cash Burn Rate Simply Wall St.
Mar-16-20 12:09AM	'This can happen to anyone': How this cell therapy pioneer, diagnosed with the coronavirus, wants to destigmatize COVID-19 American City Business Journals -16.64%
Mar-02-20 06:15AM	Will Allogene Continue to Surge Higher? Zacks
Mar-01-20 07:15AM	Sen. Dianne Feinsteins Husband Sold a Biotech Stock Near Its 2020 Low Barrons.com
Feb-27-20 04:30AM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-19-20 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020 GlobeNewswire
Feb-06-20 08:30AM	Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule GlobeNewswire +6.83%
Jan-13-20 06:00AM	Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma GlobeNewswire
Jan-02-20 08:30AM	Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-19 05:16PM	Is Allogene Therapeutics, Inc. (ALLO) A Good Stock To Buy? Insider Monkey
Nov-11-19 08:30AM	Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule GlobeNewswire
Nov-06-19 09:02AM	Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T Pipeline at 61st American Society of Hematology Annual Meeting GlobeNewswire -6.40%
Nov-05-19 07:30AM	Allogene Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
06:28AM	Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications GlobeNewswire
Oct-29-19 08:30AM	Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019 GlobeNewswire
Oct-25-19 11:12AM	Is Allogene Therapeutics, Inc. (ALLO) A Good Stock To Buy? Insider Monkey
Oct-18-19 11:22AM	New Gilead CFO: Let's Make a Deal GuruFocus.com

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHMIDT ERIC THOMAS	Chief Financial Officer	Jan 15	Sale	32.26	15,000	483,859	1,152,595	Jan 19 04:31 PM
SCHMIDT ERIC THOMAS	Chief Financial Officer	Jan 14	Sale	30.77	15,000	461,610	1,167,595	Jan 19 04:31 PM
Bhavnagri Veer	General Counsel	Dec 17	Option Exercise	2.27	51,500	116,905	405,402	Dec 18 04:34 PM
SCHMIDT ERIC THOMAS	Chief Financial Officer	Nov 16	Sale	32.88	15,000	493,146	1,182,595	Nov 18 04:36 PM
SCHMIDT ERIC THOMAS	Chief Financial Officer	Oct 15	Sale	40.49	15,000	607,392	1,197,595	Oct 16 06:55 PM
MOORE ALISON	Chief Technical Officer	Oct 13	Option Exercise	2.27	11,031	25,040	119,401	Oct 13 04:34 PM
MOORE ALISON	Chief Technical Officer	Oct 13	Sale	42.00	11,031	463,302	108,370	Oct 13 04:34 PM
MOORE ALISON	Chief Technical Officer	Oct 12	Option Exercise	2.27	24,233	55,009	132,603	Oct 13 04:34 PM
MOORE ALISON	Chief Technical Officer	Oct 12	Sale	42.00	24,233	1,017,786	108,370	Oct 13 04:34 PM
MOORE ALISON	Chief Technical Officer	Oct 09	Option Exercise	2.27	30,199	68,552	147,879	Oct 09 05:49 PM
MOORE ALISON	Chief Technical Officer	Oct 09	Sale	41.00	39,509	1,619,869	108,370	Oct 09 05:49 PM
MOORE ALISON	Chief Technical Officer	Oct 08	Option Exercise	2.27	5,065	11,498	122,745	Oct 09 05:49 PM
MOORE ALISON	Chief Technical Officer	Oct 08	Sale	41.00	5,065	207,665	117,680	Oct 09 05:49 PM
Amado Rafael	EVP of R&D and CMO	Oct 07	Sale	39.40	16,538	651,515	111,677	Oct 08 05:10 PM
Bhavnagri Veer	General Counsel	Oct 06	Option Exercise	2.27	10,000	22,700	363,902	Oct 08 05:01 PM
MOORE ALISON	Chief Technical Officer	Oct 06	Option Exercise	2.27	35,264	80,049	161,536	Oct 08 05:03 PM
MOORE ALISON	Chief Technical Officer	Oct 06	Sale	40.00	44,574	1,782,960	117,680	Oct 08 05:03 PM
Bhavnagri Veer	General Counsel	Oct 06	Sale	40.00	10,000	400,000	353,902	Oct 08 05:01 PM
Bhavnagri Veer	General Counsel	Oct 01	Option Exercise	2.27	25,000	56,750	378,902	Oct 02 04:42 PM
Bhavnagri Veer	General Counsel	Oct 01	Sale	36.52	25,000	912,913	353,902	Oct 02 04:42 PM
Amado Rafael	EVP of R&D and CMO	Oct 01	Sale	36.37	9,752	354,662	128,215	Oct 02 04:40 PM
SCHMIDT ERIC THOMAS	Chief Financial Officer	Sep 21	Sale	35.30	15,000	529,545	1,212,595	Sep 22 04:48 PM
Bhavnagri Veer	General Counsel	Sep 01	Option Exercise	2.27	25,000	56,750	378,902	Sep 03 04:12 PM
Bhavnagri Veer	General Counsel	Sep 01	Sale	35.36	25,000	883,966	353,902	Sep 03 04:12 PM
MOORE ALISON	Chief Technical Officer	Aug 13	Option Exercise	2.27	32,451	73,664	126,272	Aug 14 04:04 PM
TPG Group Holdings (SBS) Advis	10% Owner	Aug 07	Sale	37.41	13,291	497,236	18,716,306	Aug 10 04:34 PM
TPG Group Holdings (SBS) Advis	10% Owner	Aug 06	Sale	37.50	24,154	905,794	18,729,597	Aug 10 04:34 PM
Bhavnagri Veer	General Counsel	Aug 03	Option Exercise	2.27	25,000	56,750	385,455	Aug 05 05:09 PM
Bhavnagri Veer	General Counsel	Aug 03	Sale	36.89	31,553	1,164,121	353,902	Aug 05 05:09 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 30	Sale	42.21	59,747	2,522,052	19,716,306	Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 29	Sale	43.27	24,904	1,077,544	19,776,053	Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 26	Sale	44.01	500	22,005	19,800,957	Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 25	Sale	44.19	72,359	3,197,327	19,801,457	Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 24	Sale	43.93	15,269	670,714	19,873,816	Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 23	Sale	43.98	132,225	5,814,610	19,889,085	Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 22	Sale	42.83	172,425	7,384,721	20,021,310	Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 19	Sale	42.04	47,767	2,008,306	20,193,735	Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 18	Sale	42.14	94,600	3,986,595	20,241,502	Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 17	Sale	42.18	87,319	3,683,482	20,336,102	Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 16	Sale	42.20	174,511	7,364,678	20,423,421	Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 15	Sale	42.14	129,154	5,442,885	20,597,932	Jun 17 06:13 PM
Belldegrun Arie	Director	Jun 04	Buy	47.00	146,382	6,879,954	1,798,163	Jun 04 04:04 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 04	Sale	47.11	1,818	85,638	20,727,086	Jun 05 05:43 PM
TPG Group Holdings (SBS) Advis	10% Owner	Jun 03	Sale	47.40	487,402	23,102,514	20,728,904	Jun 05 05:43 PM
SCHMIDT ERIC THOMAS	Chief Financial Officer	Mar 16	Sale	19.73	5,450	107,508	47,257	Mar 18 04:32 PM
MOORE ALISON	Chief Technical Officer	Mar 16	Sale	19.19	3,750	71,980	63,021	Mar 18 04:32 PM
Chang David D	President and CEO	Mar 16	Sale	19.31	20,335	392,615	2,214,914	Mar 18 04:31 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience